Neurologists value speed and efficacy over safety for ALS pipeline drugs, study finds
Neurologists who were asked about new treatments for amyotrophic lateral sclerosis (ALS) say they value efficacy and quality-of-life improvements over safety for drugs in development.
The typically rapid progression of the terminal disease is the chief factor in the safety sentiment, said Alissa Algarin, senior insights analyst at Spherix Global Insights. As one neurologist told the surveyors: “In a condition like this, I’m more towards efficacy because if you’re dead it doesn’t matter how safe the drug was.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.